Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the Omni Ultra Surgical System (Omni Ultra) for canaloplasty followed by trabeculotomy for the reduction of intraocular pressure (IOP) in adult patients with primary open-angle glaucoma (POAG).

BlueWind Medical announced today that it received FDA 510(k) clearance for Revi Extend, its next-generation implant.